Sustained release intraocular implants and related methods

• US 20130017244A1
• Filed: 09/13/2012
• Published: 01/17/2013
• Est. Priority Date: 04/30/2004
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Huang, Glenn T., Nivaggioli, Therry
• Granted Patent: US 8,440,216 B2
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/14 Decongestants or antiallergics

Abstract

Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

Claims

1-50. -50. (canceled)

51. A method of treating an ocular condition of a patient, comprising the step of placing an intraocular implant in an eye of the patient to provide a therapeutically effective amount of a steroid to the patient for about one year, wherein said implant comprises a polymeric outer layer covering a core containing a steroid, the polymeric outer layer including a plurality of holes sized to permit the steroid to pass from the implant to an external environment at a rate of less than 2 μ

g/day for about one year after the implant is placed in an eye of a patient, wherein each of the holes has a diameter of at least about 250 μ

m and less than about 500 μ

m.

52. The method of claim 51, wherein the ocular condition is an inflammation of the eye.

53. The method of claim 51, wherein the implant is placed in the posterior of the eye.

54. The method of claim 51, wherein the implant is placed in the eye with a trocar.

55. The method of claim 51, wherein the implant is placed in the eye with a syringe.

56. The method of claim 51, further comprising a step of administering a therapeutic agent in addition to the steroid to the patient.

59. The method of claim 51, wherein the ocular condition is uveitis.

57. (canceled)

58. (canceled)